Biological Roles, Prognostic Significance, and Therapeutic Potential of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma: A Narrative Review
Oral squamous cell carcinoma (OSCC) is characterized by marked intratumoral heterogeneity, frequent recurrence, and variable responses to treatment. Cancer stem cells (CSCs) are thought to contribute to these features through their capacity for self-renewal, tumor initiation, phenotypic plasticity, and resistance to therapy. This narrative review summarizes the biological and clinical significance of major CSC-associated markers in OSCC, with a focus on ALDH1, CD44, CD133, SOX2, OCT4, and NANOG. Current evidence suggests that CSC phenotypes are dynamically regulated by epithelial–mesenchymal plasticity, hypoxia, the tumor microenvironment, and signaling pathways including Wnt/β-catenin, Notch, Hedgehog, PI3K/AKT/mTOR, Hippo-YAP/TAZ, and TGF-β. The expression of these markers has been associated with tumor initiation, invasion, metastasis, recurrence, treatment resistance, and patient survival. However, their prognostic significance remains inconsistent across studies because of tumor heterogeneity, limited marker specificity, differences in isoforms and assay methods, and variability in scoring systems and cut-off values. Consequently, no single CSC marker is currently adequate for routine clinical use. Importantly, most CSC-targeted therapeutic strategies remain supported primarily by in vitro and animal studies, and their clinical efficacy in patients with OSCC has not yet been established. Future approaches integrating multi-marker panels with spatially resolved analyses, single-cell and spatial omics, patient-derived models, and liquid biopsy may improve risk stratification and treatment selection. Prospective multicenter validation and methodological standardization are required before CSC-based biomarkers and therapeutic strategies can be incorporated into precision oncology for OSCC.